| Document |
Document Title |
|
WO/2023/186945A1 |
The present invention relates to the cosmetic, nutraceutical use of a Lactobacillus crispatus strain and/or of a composition comprising same to decrease the pigmentation of the skin and/or of the mucous membranes and/or prevent the incre...
|
|
WO/2023/192351A1 |
Described herein are methods and compositions for treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a ...
|
|
WO/2023/192408A1 |
Disclosed are compounds of the formula (I): wherein R1-R5, X, Y1 and Y2 are as defined in the specification, pharmaceutical salts thereof and stereoisomers thereof, and pharmaceutical compositions containing one or more of these compound...
|
|
WO/2023/186957A1 |
The present invention concerns an aqueous solution comprising molecular hydrogen and at least one salt, wherein said solution has an ionic strength in the range from 0.001 mol/l to 1 mol/l and comprises ascorbic acid or a salt thereof. T...
|
|
WO/2023/184114A1 |
The present application provides a polypeptide and a cosmetic composition or pharmaceutical composition and use thereof. The polypeptide has the following general formula: R1-X1-X2-X3-X4-X5-X6-X7-X8-R2. The present application relates to...
|
|
WO/2023/191204A1 |
The present invention relates to a peptide composition having angiogenic activity, and a pharmaceutical composition using same and a cosmetic composition using same. The peptide forms a hydrogen bond with nicotinamide mononucleotide, whi...
|
|
WO/2023/190826A1 |
The present invention relates to a pharmaceutical composition for preventing, suppressing, or treating the symptoms that accompany pseudo-allergic reactions, said pharmaceutical composition comprising, as an active ingredient, a compound...
|
|
WO/2023/191016A1 |
This fibrillin production promoter contains a pyrimidine nucleotide or a precursor thereof as an active ingredient.
|
|
WO/2023/191196A1 |
The present invention relates to a composition for reducing skin photoaging, comprising Pediococcus acidilactici LM1013 (KCTC12039BP) as an active ingredient. The composition for reducing skin photoaging, comprising Pediococcus acidilact...
|
|
WO/2023/184986A1 |
The present invention provides use of a CD36 inhibitor in preparing a medicament for inhibiting scarring after spinal cord injury. The present invention relates to the field of biotechnology, and particularly to use of a CD36 inhibitor i...
|
|
WO/2023/189035A1 |
A composition according to the present invention contains, as active ingredients, the following components (1), (2), (3), and (4). Component (1): At least one herbal medicine selected from the group consisting of Ligustrum fruit, yerba...
|
|
WO/2023/185638A1 |
A crystal form of a quinoline derivative and a preparation method therefor. The crystal form of a quinoline derivative has good stability, fluidity, compressibility, solubility, bioavailability and the like, so that a wide selection of a...
|
|
WO/2023/191665A1 |
The invention relates, in particular, to monoclonal antibodies that specifically bind to an alpha chain of the receptor to human interleukin 4 (hIL-4Rα) and have reduced immunogenic activity as compared with an antibody dupilumab, which...
|
|
WO/2023/191515A1 |
The present invention relates to a composition for preventing hair loss or promoting hair growth, comprising an indirubin derivative and a metabolic activator. The composition, according to the present invention, may be effectively used ...
|
|
WO/2023/189321A1 |
Provided are: an atopic dermatitis ameliorating agent comprising a glyceryl ascorbic acid acylated derivative having a specific molecular structure; etc.
|
|
WO/2023/187198A1 |
The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, for treating and/or preventing, in an individual in need thereof, a disorder characterized by a CXCL5 level higher in a biological sample of said i...
|
|
WO/2023/190518A1 |
The present invention inhibits oxidative stress. An oxidative stress inhibitor that comprises a compound represented by general formula (I) or a salt thereof exclusively as an active ingredient. (In the formula, R1 to R9 are the same or ...
|
|
WO/2023/190117A1 |
The present disclosure addresses the problem of providing a method for producing a new ellagic acid-containing composition capable of improving solubility of ellagic acid. The present embodiment is a method for producing an ellagic acid-...
|
|
WO/2023/182856A1 |
The present invention relates to a pharmaceutical composition and a skin topical composition, each including a Rho-kinase inhibitor as an active ingredient for the prevention or treatment of skin fibrotic disorders, and a method for the ...
|
|
WO/2023/180576A1 |
The invention relates to pharmaceutical matrix tablets for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or h...
|
|
WO/2023/182579A1 |
The composition comprising potassium all-trans retinoate (PATRA) for inhibiting skin inflammation in acne and photoaging patients having high levels of inflammatory proteins and residual skin components secreted from the skin exhibits hi...
|
|
WO/2023/182192A1 |
The objective of the present invention is to provide a composition which is for inhibiting Pseudomonas syringae, contains alcohol, and can inhibit the growth of Pseudomonas syringae while inhibiting the production of IL-1α caused by the...
|
|
WO/2023/180661A1 |
The present invention relates to the novel cosmetic or dermatological use of an extract of Dendrobium officinale and/or of a composition comprising same for maintaining and/or increasing the thickness of the skin, preferably of the epide...
|
|
WO/2023/180564A1 |
Biocompatible antiseptic composition containing 9-hydroxycalabaxanthone and/or related xanthones The present invention relates to a cosmetic or pharmaceutical composition containing 9-hydroxycalabaxanthone in the form of gel, aqueous sol...
|
|
WO/2023/181563A1 |
Provided is an anti-adhesive material containing particles, in which the particles comprise a crosslinked product of a gelatin mixture composed of a first gelatin and a second gelatin having such a structure that a hydrocarbon group is i...
|
|
WO/2023/183396A1 |
Provided herein are methods and compositions related to Prevotella bacteria useful as therapeutic agents, e.g., for the treatment of inflammatory disease.
|
|
WO/2023/178592A1 |
Disclosed herein is a method of treating diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils. The method includes administering to a subject in need thereof an effective amount of an extra...
|
|
WO/2023/179905A1 |
The present application relates to a combination of 5-amino-2,3-dihydro-1,4- phthalazinedione or one of its pharmaceutically acceptable salts and at least one fumaric acid ester or a pharmaceutically acceptable salt thereof. In particula...
|
|
WO/2023/178861A1 |
Provided in the present invention are the use of platelet-derived growth factor in preparation of a medicine for treating burns and scalds. When being used to prepare an external application preparation for treating burns and scalds of a...
|
|
WO/2023/180281A1 |
The present invention refers to peptides which provide for the protection of telomeres, antioxidant and anti-inflammatory activities and, hence, are useful in cosmetics for the prevention, reduction and/or treatment of inflammaging and s...
|
|
WO/2023/180575A1 |
The invention relates to solid dispersions for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: For...
|
|
WO/2023/183059A1 |
The present invention provides a method of treating pathological inflammation in a patient comprising: administering to the patient a multivalent structured polypeptide comprising at least one therapeutic peptide. The present invention a...
|
|
WO/2023/181755A1 |
Provided is: a highly-safe and low-cost expression regulator for a factor particularly involved in maturation, moisture retention, or barrier function of the skin; an expression enhancer for an antimicrobial peptide; an expression enhanc...
|
|
WO/2023/182468A1 |
The present disclosure provides a wound treatment composition and the like. N-(\{2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3-ox
azol-4-yl\}methyl)-2-ethoxybenzamide or a salt thereof is useful as an active ingredient of the woun...
|
|
WO/2023/180214A1 |
The invention relates to compositions, particularly topical compositions comprising a urolithin, cosmetic compositions comprising a urolithin and cosmetic compositions comprising a urolithin and trehalose, compositions comprising urolith...
|
|
WO/2023/183901A1 |
Compounds, compositions thereof, and methods of using the same in dosing protocols for the inhibition of TYK2, and the treatment of inflammatory disorders including psoriasis and psoriatic arthritis are described.
|
|
WO/2023/114833A9 |
The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and rezpegaldesleukin, and formulations and dosing regimens for methods of using these compositions, for example, fo...
|
|
WO/2023/174447A1 |
Disclosed are a mesenchymal stem cell wound repair dominant functional cluster (Hr-MSC), identification thereof, and an application. The mesenchymal stem cell wound repair dominant functional cluster has a biomarker combination comprisin...
|
|
WO/2023/178219A1 |
The present disclosure concerns use of activated or inactivated fibroblasts or fibroblast-derived materials, such as exosomes from fibroblasts, for wound care. The methods and compositions are useful for purpose of tissue differentiation...
|
|
WO/2023/174205A1 |
The present invention relates to a pharmaceutical formulation and use thereof, belonging to the field of pharmacy. The pharmaceutical formulation has significant effects in preventing and treating renal diseases, eye diseases, ulcerative...
|
|
WO/2023/178256A1 |
The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib o...
|
|
WO/2023/177207A1 |
The present invention relates to a scalp or hair care composition comprising a nano-carbon structure, and the nano-carbon structure of the present invention can retain moisture of the scalp or hair even in a small amount, and relieve inf...
|
|
WO/2023/178099A1 |
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/176952A1 |
The purpose of the present invention is to provide a means for controlling the proliferation of a bacterium in the intestine. Provided is a composition for controlling the proliferation of any one bacterium selected from the group consis...
|
|
WO/2023/176951A1 |
Provided is a means for controlling proliferation of Collinsella bacteria in the intestines. The present invention addresses the problem of providing a novel material that is capable of controlling proliferation of Collinsella bacteria. ...
|
|
WO/2023/177625A1 |
Disclosed herein are shelf-stable formulations comprising benzoyl peroxide in a formulation effective to reduce or prevent degradation of the benzoyl peroxide to benzene. Further provided herein are methods of preventing or reducing degr...
|
|
WO/2023/178269A1 |
The present disclosure relates to methods for treating cutaneous neurofibromas (cNF) comprising administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/174981A1 |
The present invention relates to an aqueous extract obtained from a plant of the genus Aster for cosmetic or therapeutic applications, in particular in the prevention and/or treatment of acne.
|
|
WO/2023/174039A1 |
Disclosed herein are anti-MASP-2 antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Us...
|
|
WO/2023/176796A1 |
The problem to be solved by the present invention is to provide a novel scar formation inhibitor having, as an active ingredient, a compound that has not been conventionally known to have an effect for inhibiting scar formation. The pres...
|
